LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Accueil・Liste d'Actions・Kura Oncology Inc

Kura Oncology Inc

Fermé

SecteurSoins de santé

8.81 1.85

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.58

Max

8.99

Chiffres clés
By Trading Economics
Revenu	7.7M -73M
Ventes	929K 18M
BPA	-0.828
Marge bénéficiaire	-401.495
Employés	260
EBITDA	7.4M -78M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+228.39% upside

Dividendes
By Dow Jones
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-42M 802M
Ouverture précédente	6.96
Clôture précédente	8.81

Sentiment de l'Actualité

By Acuity

100%

320 / 344 Classement par Healthcare

Kura Oncology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 juin 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 juin 2026, 15:41 UTC

Principaux Mouvements du Marché

American Battery Shares Jump on Energy Department Victory

8 juin 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 juin 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 juin 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 juin 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 juin 2026, 21:57 UTC

Acquisitions, Fusions, Rachats

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 juin 2026, 21:56 UTC

Acquisitions, Fusions, Rachats

Salesforce Agrees to Buy m3ter

8 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 juin 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 juin 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 juin 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 juin 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 juin 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 juin 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 juin 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 juin 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 juin 2026, 16:55 UTC

Acquisitions, Fusions, Rachats

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 juin 2026, 16:54 UTC

Acquisitions, Fusions, Rachats

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 juin 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 juin 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 juin 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 juin 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 juin 2026, 16:03 UTC

Acquisitions, Fusions, Rachats

Orange Bought Stake From Lorca

8 juin 2026, 16:01 UTC

Acquisitions, Fusions, Rachats

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 juin 2026, 16:01 UTC

Acquisitions, Fusions, Rachats

Orange Acquires 100% Ownership of MasOrange

8 juin 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 juin 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 juin 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 juin 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparaison

Variation de prix

Kura Oncology Inc prévision

Objectif de Prix

By TipRanks

228.39% hausse

Prévisions sur 12 Mois

Moyen 28.11 USD 228.39%

Haut 40 USD

Bas 15 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

Achat

Maintien

Vente

Basé sur 10 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

320 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.